Role of liquid biopsy for thoracic cancers immunotherapy
Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the lack of tissue sample availability for clinical and research purposes. In this scenario, liquid biops...
Main Authors: | Raimondo Di Liello, Flora Cimmino, Soraya Simón, Emilio Francesco Giunta, Vincenzo De Falco, Paloma Martín-Martorell |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration Publishing Inc.
2020-06-01
|
Series: | Exploration of Targeted Anti-tumor Therapy |
Subjects: | |
Online Access: | https://www.explorationpub.com/Journals/etat/Article/100212 |
Similar Items
-
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
by: Edoardo Lenci, et al.
Published: (2021-06-01) -
Recommendations for clinical use of tumor markers in lung cancer
by: Stanković Sanja
Published: (2007-01-01) -
Thymidylate synthase inhibitors for thoracic tumors
by: Peters Godefridus J., et al.
Published: (2013-06-01) -
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
by: Nagasaka M, et al.
Published: (2019-09-01) -
Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies
by: Si-Cong Ma, et al.
Published: (2021-01-01)